首页> 美国政府科技报告 >Gene Expression Profile of BRCAness That Predicts for Responsiveness to Platinum and PARP Inhibitors.

【24h】

Gene Expression Profile of BRCAness That Predicts for Responsiveness to Platinum and PARP Inhibitors.

机译：预测对铂和paRp抑制剂的响应性的BRCaness的基因表达谱。

获取原文

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Konstantinopoulos, P.;
展开▼
作者单位

展开▼
年度 2017
页码 1-32
总页数 32
原文格式 PDF
正文语种 eng
中图分类
关键词
Ovarian cancer; Chemotherapy; Neoplasms; Gene expression; Metabolic diseases; Lymphocytes; Therapeutics; Clinical trials; Breast cancer; Oncology; Inhibitors; Proteins; Ovarian cancer; Homologous recombination; Brcaness; Parp inhibitors; Hsp90 inhibitors;

机译：卵巢癌;化学疗法;肿瘤;基因表达;代谢疾病;淋巴细胞;治疗学;临床试验;乳腺癌;肿瘤学;抑制剂;蛋白质;卵巢癌;同源重组; Brcaness; parp抑制剂; Hsp90抑制剂;

相似文献

外文文献
中文文献
专利

1. Expression of DNA Damage Response Molecules PARP1, γH2AX, BRCA1, and BRCA2 Predicts Poor Survival of Breast Carcinoma Patients [J] . See-Hyoung Park, Sang Jae Noh, Kyoung Min Kim, Translational Oncology . 2015,第4期

机译：DNA损伤反应分子PARP1，γH2AX，BRCA1和BRCA2的表达预测乳腺癌患者的不良生存
2. Predictive value of ATP7b, BRCA1, BRCA2, PARP1, UIMC1 (RAP80), HOXA9, DAXX, TXN (TRX1), THBS1 (TSP1) and PRR13 (TXR1) genes in patients with epithelial ovarian cancer who receivedplatinum-taxane first-line therapy [J] . Pontikakis S., Papadaki C., Tzardi M., The pharmacogenomics journal . 2017,第6期

机译：患有上皮卵巢癌患者的ATP7B，BRCA1，BRCA2，PARP1，UIMC1（RAP80），HOXA9，DAXX，TXN（TRX1），TX1（TSP1）和PRR13（TXR1）基因的预测值
3. Platinum and PARP Inhibitor Resistance Due to Overexpression of MicroRNA-622 in BRCA1-Mutant Ovarian Cancer [J] . Young?Eun Choi, Khyati Meghani, Marie-Eve Brault, Cell Reports . 2016,第3期

机译：由于MicroRNA-622在BRCA1突变型卵巢癌中的过表达而导致的铂和PARP抑制剂抗性。
4. Analysis of Different Pre-Processing Techniques to the Development of Machine Learning Predictors with Gene Expression Profiles [C] . Ian Durán, Roberto Leandro, Jose Guevara-Coto Jornadas Costarricenses de Investigacion en Computacion e Informatica . 2019

机译：具有基因表达谱的机器学习预测器开发中的不同预处理技术分析
5. Reliability of a statistical instrument for predicting BRCA1/BRCA2 genetic mutation carrier status. [D] . Phillips, Marcia Ann. 2002

机译：预测BRCA1 / BRCA2基因突变携带者状态的统计工具的可靠性。
6. Platinum and PARP inhibitor resistance due to over-expression of microRNA-622 in BRCA1-mutant ovarian cancer [O] . Young Eun Choi, Khyati Meghani, Marie-Eve Brault, -1

机译：microRNA-622在BRCA1突变型卵巢癌中的过表达导致铂和PARP抑制剂耐药
7. Individual and Combined Expression of DNA Damage Response Molecules PARP1, γH2AX, BRCA1, and BRCA2 Predict Shorter Survival of Soft Tissue Sarcoma Patients. [O] . Kyoung Min Kim, Young Jae Moon, See-Hyoung Park, 2016

机译：DNa损伤反应分子paRp1，γH2aX，BRCa1和BRCa2的个体和组合表达预测软组织肉瘤患者的较短存活率。
8. Gene Expression Profile of BRCAness that Predicts for Responsiveness to Platinum and PARP Inhibitors. [R] . Konstantinopoulos, P. 2014

机译：BRCaness的基因表达谱预测对platinum和paRp抑制剂的反应性。

Gene Expression Profile of BRCAness That Predicts for Responsiveness to Platinum and PARP Inhibitors.

著录项

引文网络

相似文献

相关主题

期刊订阅